News - Par Pharmaceutical, Santarus

Filter

Popular Filters

Par Pharmaceutical to acquire JHP Pharmaceutical

21-01-2014

US privately-held Par Pharmaceutical has entered into a definitive agreement to acquire JHP Group Holdings,…

GenericsJHP PharmaceuticalsMergers & AcquisitionsPar Pharmaceutical

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

08-11-2013

Salix Pharmaceuticals has entered into a definitive merger agreement to acquire all the outstanding common…

DiabetesGastro-intestinalsGlumetzaMergers & AcquisitionsPharmaceuticalRare diseasesRuconestSalix PharmaceuticalsSantarus

Acura Pharma settles with Par and Impax over Oxecta

Acura Pharma settles with Par and Impax over Oxecta

11-10-2013

US specialty pharma firm Acura Pharmaceuticals saw its shares leap as much as 28% after it said that…

Acura PharmaceuticalsGenericsImpax LaboratoriesLicensingNeurologicalNorth AmericaOxectaPar PharmaceuticalPatents

Horizon Pharma in Duexis patent settlement

22-08-2013

Horizon Pharma (Nasdaq: HZNP) says it has entered into settlement and license agreements with Par Pharmaceutical…

Anti-Arthritics/RheumaticsDuexisGenericsHorizon PharmaNorth AmericaPar PharmaceuticalPatentsPharmaceutical

US FDA accepts Ruconest filing from Santarus and Pharming

18-06-2013

US drugmaker Santarus (Nasdaq: SNTS) and Netherlands-based Pharming Group (NYSE Euronext: PHARM) say…

BiotechnologyCardio-vascularNorth AmericaPharmingRare diseasesRegulationRuconestSantarus

Pharming and Santarus file BLA for Ruconest with US FDA

18-04-2013

Netherlands-based Pharming Group (NYSE Euronext: PHARM) and US licensee Santarus (Nasdaq: SNTS) have…

North AmericaPharmaceuticalPharmingRare diseasesRegulationRuconestSantarus

Par Pharma agrees $45 million settlement over off-label Megace ES promotion

07-03-2013

US generic drugmaker Par Pharmaceutical NYSE: PRX) pleaded guilty in federal court yesterday (March 6)…

FinancialGenericsLegalMarkets & MarketingMegace ESMetabolicsNorth AmericaPar PharmaceuticalPharmaceutical

Pharming gets $10 million milestone from Santarus on Ruconest progress

26-11-2012

Loss-making Dutch biotech company Pharming Group NV (NYSE Euronext: PHARM) said yesterday that, following…

BiotechnologyFinancialPharmingRare diseasesResearchRuconestSantarus

Validity of certain patent claims covering Santarus' Zegerid capsule and powder upheld

06-09-2012

US drugmaker Santarus (Nasdaq: SNTS) saw its shares leap 14.2% to $7.06 in regular trading on September…

GenericsLegalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSantarusZegerid

Mylan settles litigation with Somaxon relating to its generic Silenor

19-07-2012

US generic drugmaker Mylan (Nasdaq: MYL) and its subsidiary, Mylan Pharmaceuticals have entered into…

LegalMylan LaboratoriesNeurologicalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSilenorSomaxon Pharmaceuticals

TPG to acquire Par Pharma for $1.9 billion

17-07-2012

Par Pharmaceutical (NYSE: PRX), a USA-based maker of generic drugs and niche innovative proprietary pharmaceuticals,…

GenericsMergers & AcquisitionsPar PharmaceuticalTPG

FDA decides Teva is sole first-to-file on Provigil; Mylan argues ruling

09-04-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) said on April 5 that the US Food and Drug…

CephalonGenericsLegalModafinilMylan LaboratoriesNeurologicalNorth AmericaPar PharmaceuticalProvigilRegulationTeva Pharmaceutical Industries

Horizon Pharma sues Par for infringing Duexis patent

29-03-2012

Horizon Pharma (Nasdaq: HZNP) has filed a patent infringement lawsuit in the US District Court for the…

DuexisGenericsHorizon PharmaLegalNeurologicalNorth AmericaPar PharmaceuticalPatents

NovaDel regains rights for ondansetron oral spray product

22-01-2012

New Jersey, USA-based NovaDel Pharma (OTCBB: NVDL) has announced the termination of certain license agreements…

BioAlliance PharmaLicensingNovaDel PharmaOncologyondansetronPar PharmaceuticalPharmaceuticalTalon Therapeutics

Promotions at Par Pharma as firm grows with acquisitions

22-11-2011

US generics drugmaker Par Pharmaceutical (NYSE: PRX) has promoted Thomas Haughey to the role of president…

GenericsManagementPar Pharmaceutical

Santarus and Depomed expand US deal on Glumetza

23-08-2011

US drugmakers Santarus (Nasdaq: SNTS) and Depomed (Nasdaq: DEPO) have entered into a new commercialization…

DepomedDiabetesGlumetzaLicensingNorth AmericaPharmaceuticalSantarus

Par Pharma to buy Indian generics group Edict for $37.6 million plus debt

24-05-2011

US generics and niche drug company Par Pharmaceutical (NYSE: PRX) has entered into a definitive agreement…

Asia-PacificEdict PharmaceuticalsGenericsMergers & AcquisitionsPar Pharmaceutical

Company Spotlight

Fibrotech

Fibrotech

Back to top